Sarepta turns to Duke’s CRISPR work for next-gen DMD therapies – FierceBiotech
|
Sarepta turns to Duke's CRISPR work for next-gen DMD therapies
FierceBiotech Sarepta says it will collaborate with Gersbach's lab to “advance the CRISPR platform and take the lead on clinical development.” It's signed a series of similar deals, including in gene therapy, to help it create better, broader treatments for the … |
